Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
| The following article is part of conference coverage from the American Diabetes Association’s 78th Scientific Sessions (ADA 2018) in Orlando,Florida. Endocrinology Advisor’s staff will report on medical research and technological advances in diabetes and diabetes education, conducted by experts in the field. Check back for the latest news from ADA 2018. |
ORLANDO — In patients with type 2 diabetes, MEDI0382 safely and effectively normalizes fasting/postprandial blood glucose and significantly reduces body weight, according to results presented at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Florida, June 22-26, 2018.
The study included participants with type 2 diabetes and body mass index (BMI) of 27 to 40 kg/m2 (n=51). Participants were randomly assigned to receive daily subcutaneous MEDI0382 200 μg or placebo (NCT02548585).
Participants who took MEDI0382 had significantly reduced fasting glucose (change from baseline at day 41, −49.9 vs −19.2 mg/dL; P <.0001) and postprandial glucose in a mixed-meal tolerance test (percent change from baseline in glucose area under the curve0-4h, −32.8 vs −10.2; P <.0001). There was no increase in hypoglycemia.
In participants who took MEDI0382, glycated hemoglonin A1c (HbA1c) levels decreased −0.9% compared with −0.6% with placebo (P =.0004). Participants in the MEDI0382 group lost 3.8 kg (1.7 kg more than the placebo group), with 92% of MEDI0382 participants losing >2 kg. MEDI0382 participants had a −4.2 mean reduction in ambulatory systolic blood pressure compared with −1.5 mmHg with placebo.
The most common treatment-related adverse events were decreased appetite, vomiting, and headache, which were reported by 20 participants in the MEDI0382 group and 15 in the placebo group.
For more coverage of ADA 2018, click here.
Reference
Ambery P, Stumvoll MW, Posch MG, et al. Robust glucose control and weight loss after six weeks of treatment with MEDI0382, a balanced GLP-1/glucagon receptor dual agonist, in patients with type 2 diabetes. Presented at the ADA 2018 78th Scientific Sessions; June 22-26, 2018; Orlando, Florida. Poster 1067.
